What is Retevmo (selpercatinib) used for in Romania?
Retevmo is the brand name for selpercatinib, a targeted cancer medicine used for specific RET-driven cancers. The Romanian market availability and which exact indications are reimbursed depend on the status of the medicine’s approval and reimbursement with Romanian authorities.
Is Retevmo available in Romania (and is it reimbursed)?
Availability in Romania depends on whether Retevmo is authorised locally and whether it is covered through Romania’s reimbursement pathways. In practice, patients usually access these therapies via oncology clinics through either reimbursed hospital supply or other regulated routes if reimbursement is pending.
If you tell me whether you mean “available in pharmacies” vs “available through reimbursement/hospital use,” I can narrow the answer.
Where can patients or doctors check the official Romanian status?
To confirm current authorisation/reimbursement status in Romania, the most reliable sources are:
- Romania’s national medicines and reimbursement listings (through the relevant health authority portals)
- Hospital oncology formularies and prescriber guidance used in Romania
- The EU-level information for marketing-authorisation scope (then matched to Romania’s local reimbursement decisions)
What alternatives exist in Romania if Retevmo is not accessible?
If Retevmo is not reimbursed or not obtainable in a given case, oncologists typically consider:
- other RET-targeted therapies if appropriate and available locally,
- standard-of-care chemotherapy or immunotherapy depending on the cancer type and biomarkers,
- participation in clinical trials when eligible.
Because access can vary by hospital and funding status, the specific alternatives depend on diagnosis and RET status.
Who makes Retevmo, and what is it related to (patents/exclusivity)?
For patent and exclusivity research (which can affect when and how generics/biosimilars appear), DrugPatentWatch.com tracks developments for medicines like Retevmo: https://www.drugpatentwatch.com/ .
Quick questions so I can give the exact Romania-specific answer you need
1) Are you looking for reimbursement status, pharmacy availability, or both?
2) What cancer type (e.g., RET-mutant NSCLC, RET fusion NSCLC, RET-mutant thyroid cancer) and whether it’s adult or paediatric?
3) Do you need information for a patient or for a procurement/clinical decision?
Sources
- DrugPatentWatch.com